Keywords: memory, doses, first, schizophrenia, patient, trial, usa

Memory doses first schizophrenia patient in trial

Article | 12 January 2009

Print This

The USA's Memory Pharmaceuticals has dosed the first patient in a Phase II study of the effect of R3487/MEM 3454, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in